Ainuovirine Explained

Cas Number:

1097628-00-6

Pubchem:

25215428

Chemspiderid:

24662280

Chembl:

1081658

Pdb Ligand:

KRV

Synonyms:

ACC-007, KM-023, Aibangde, Einovirine

Iupac Name:

3-(3-ethyl-2,6-dioxo-5-propan-2-ylpyrimidine-4-carbonyl)-5-methylbenzonitrile| C=18 | H=19 | N=3 | O=3| molecular_weight = | SMILES = CCN1C(=C(C(=O)NC1=O)C(C)C)C(=O)C2=CC(=CC(=C2)C#N)C| Jmol = | StdInChI = InChI=1S/C18H19N3O3/c1-5-21-15(14(10(2)3)17(23)20-18(21)24)16(22)13-7-11(4)6-12(8-13)9-19/h6-8,10H,5H2,1-4H3,(H,20,23,24)| StdInChIKey = AYPIJAMXGVYYRQ-UHFFFAOYSA-N| density = | density_notes = | melting_point = | melting_high = | melting_notes = | boiling_point = | boiling_notes = | solubility = | sol_units = | specific_rotation = }}

Ainuovirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed by Kainos Medicine for the treatment of HIV infections.^[1] Ainuovirine was approved in China in 2021 for the treatment of HIV-1 infection.^[2]

References

Notes and References

1. Web site: Ainuovirine - Kainos Medicine . AdisInsight . Springer Nature Switzerland AG.
2. Zhang Q, Chen Z, Wang Y, Peng Y, Tan S, Li Y, Cao G, Bignotti A, Wu S, Wang M . Impacts of ainuovirine-based and efavirenz-based antiretroviral therapies on the lipid profile of HIV/AIDS patients in southern China: a real-world study . Frontiers in Medicine . 10 . 1277059 . 2023 . 38259850 . 10800701 . 10.3389/fmed.2023.1277059 . free .